ISSUE 78 I JANUARY 2019

gut

instinct

Could a recently discovered family of gut bacteria form the foundation for the first drugs using microbiome bacteria?

Antidepressants in the environment

Combating Ebola in a conflict zone

Matching patients to clinical trials

In association  with

02/23/2024 22:24:00
  • Home | Gut Instinct
  • In this issue
  • TSS Company Insight
  • TSS AB
  • International Cannabis and Cannabinoid Institute (ICCI) Company Insight
  • International Cannabis and Cannabinoid Institute (ICCI)
  • Contents
  • Daiichi Jitsugyo
  • News
  • Scandinavian Health Ltd.
  • The Pharma Industry Briefing
  • Komtur Pharmaceuticals
  • Komtur Pharmaceuticals Company Insight
  • How will the UK’s relaxed cannabis regulations impact clinical practice?
  • Finnair Cargo
  • Finnair Cargo | Company Insight
  • Developing a new class of cancer combo drugs
  • Phoenix Company Insight
  • Phoenix
  • Antidepressants in the environment: combatting pharmaceutical pollution
  • AtoZ-CRO GmbH
  • AtoZ-CRO GmbH Company Insight
  • Christensella: the key to unlocking gut microbiome-based drug discovery?
  • CBDepot
  • CBDepot Company Insight
  • Going digital to improve clinical trial enrolment
  • BEA
  • Incretin combination therapy: a breakthrough for type 2 diabetes?
  • Alpex
  • Ebola in the DRC: vaccinating in a conflict zone
  • Hemp Industries
  • Unither Pharmaceuticals
  • Data overload: turning challenges into opportunities in clinical trials
  • Zenatek
  • Solving clinical research challenges: an IT perspective
  • Pfanstiehl Company Insight
  • Pfanstiehl
  • Events
  • In the next issue
01/07/2019 00:00:00